IRIS
PORTA, Camillo Guglielmo Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.824
AS - Asia 5.611
EU - Europa 3.634
SA - Sud America 2.311
AF - Africa 259
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 4
Totale 19.652
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.563
SG - Singapore 2.228
BR - Brasile 1.782
HK - Hong Kong 855
IT - Italia 823
VN - Vietnam 682
CN - Cina 678
FR - Francia 490
RU - Federazione Russa 444
SE - Svezia 430
FI - Finlandia 414
DE - Germania 345
GB - Regno Unito 246
ID - Indonesia 230
AR - Argentina 200
IN - India 159
BD - Bangladesh 134
CA - Canada 100
EC - Ecuador 98
IQ - Iraq 91
TR - Turchia 84
MX - Messico 74
AT - Austria 73
CO - Colombia 73
JP - Giappone 71
ZA - Sudafrica 69
PK - Pakistan 66
NL - Olanda 63
SA - Arabia Saudita 53
ES - Italia 51
PH - Filippine 48
IE - Irlanda 47
VE - Venezuela 47
CI - Costa d'Avorio 46
MA - Marocco 41
UZ - Uzbekistan 38
PY - Paraguay 37
PL - Polonia 36
CL - Cile 29
JO - Giordania 20
UA - Ucraina 20
KE - Kenya 19
AL - Albania 18
AZ - Azerbaigian 18
BE - Belgio 18
EG - Egitto 18
JM - Giamaica 18
NP - Nepal 18
PE - Perù 17
MY - Malesia 16
TN - Tunisia 16
LT - Lituania 14
UY - Uruguay 13
CZ - Repubblica Ceca 12
DO - Repubblica Dominicana 12
AE - Emirati Arabi Uniti 11
BO - Bolivia 11
ET - Etiopia 10
IL - Israele 10
CH - Svizzera 9
CR - Costa Rica 9
HN - Honduras 9
OM - Oman 9
PT - Portogallo 9
RO - Romania 9
TH - Thailandia 9
AU - Australia 8
BH - Bahrain 8
KR - Corea 8
KZ - Kazakistan 8
RS - Serbia 8
DZ - Algeria 7
GT - Guatemala 7
MK - Macedonia 7
PS - Palestinian Territory 7
BG - Bulgaria 6
KG - Kirghizistan 6
LB - Libano 6
QA - Qatar 6
SN - Senegal 6
SY - Repubblica araba siriana 6
TT - Trinidad e Tobago 6
AO - Angola 5
NI - Nicaragua 5
PA - Panama 5
TW - Taiwan 5
AM - Armenia 4
BB - Barbados 4
BY - Bielorussia 4
DK - Danimarca 4
HR - Croazia 4
HU - Ungheria 4
LU - Lussemburgo 4
PR - Porto Rico 4
BA - Bosnia-Erzegovina 3
DM - Dominica 3
GE - Georgia 3
LV - Lettonia 3
MD - Moldavia 3
SV - El Salvador 3
Totale 19.590
Salva come PNG Salva come JPEG
Città #
Singapore 1.183
Ashburn 956
Hong Kong 837
Fairfield 640
San Jose 607
Helsinki 399
Cambridge 343
Nyköping 336
Lauterbourg 273
Woodbridge 262
Seattle 255
Houston 254
Bari 241
Council Bluffs 233
Wilmington 227
Chandler 223
Lawrence 219
Dallas 215
Ho Chi Minh City 210
Roxbury 201
New York 182
Jakarta 177
Los Angeles 149
Beijing 144
São Paulo 142
Paris 139
Hanoi 127
Falkenstein 121
Des Moines 120
Chicago 112
Ann Arbor 110
Dong Ket 109
Boardman 95
Santa Clara 89
Buffalo 84
San Diego 84
Inglewood 74
Nuremberg 73
London 71
Salt Lake City 65
Rio de Janeiro 55
Frankfurt am Main 50
Abidjan 46
Dublin 46
Rome 43
Belo Horizonte 41
Tokyo 41
Munich 39
Brooklyn 36
Guayaquil 36
Johannesburg 36
Vienna 34
Tashkent 33
Baghdad 32
Milan 32
Curitiba 30
Manchester 28
Porto Alegre 28
Quito 28
Da Nang 27
Medellín 27
Salvador 27
Haiphong 26
Warsaw 26
Montreal 25
Elk Grove Village 24
Istanbul 24
Toronto 23
Buenos Aires 22
Jeddah 22
Lahore 22
Phoenix 22
Brasília 21
Caracas 21
Dhaka 21
Mexico City 21
Orem 21
Atlanta 20
Campinas 20
Chennai 20
Asunción 18
Goiânia 18
Guarulhos 18
Princeton 18
Amman 17
Amsterdam 17
Bogotá 17
Moscow 17
San Francisco 17
Columbus 16
Riyadh 16
Stockholm 16
Baku 15
Denver 15
Fortaleza 15
Karachi 15
Nairobi 15
New Bedfont 15
Santiago 15
Tampa 15
Totale 11.902
Salva come PNG Salva come JPEG
Nome #
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study 245
KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation 163
Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa’ Italiana di Nefrologia (SIN) multidisciplinary consensus position paper 161
Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors 143
An update on Merkel cell carcinoma 137
The clonal heterogenicity of circulating tumor cells (CTCs) drives their metastatic potential: a new NOD‐SCID melanoma model 134
The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice 134
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial 130
Natural history of malignant bone disease in renal cancer: Final results of an italian bone metastasis survey 126
Integration of lipidomics and transcriptomics reveals reprogramming of the lipid metabolism and composition in clear cell renal cell carcinoma 123
Algorithms in the first-line treatment of metastatic clear cell renal cell carcinoma—analysis using diagnostic nodes 122
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 121
Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification 119
Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma 119
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 119
Large extracellular vesicles—a new frontier of liquid biopsy in oncology 118
Application of “omics” sciences to the prediction of bone metastases from breast cancer: State of the art 118
Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer 117
KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer 117
Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 115
Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma 115
Novel Insights into Autophagy and Prostate Cancer: A Comprehensive Review 115
Massive hyper-progression during anti-PD1 immunotherapy in a young patient with metastatic mucinous adenocarcinoma of the right colon: a case report and literature review 112
1101MO Development of CAR T-cells for future treatment of NETs 111
Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma 110
Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies 109
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial 108
Prognostic factors and current treatment strategies for renal cell carcinoma metastatic to the brain: An overview 108
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial 107
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? 107
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma 106
Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy 105
Exploring the Spectrum of Kidney Ciliopathies 103
An anti-mica/b antibody and il-15 rescue altered nkg2d-dependent nk cell responses in hepatocellular carcinoma 100
The psychological impact of COVID-19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerability 98
Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives 98
An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas 97
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: Study design and rationale 97
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 97
Biliary tract cancers: moving from the present standards of care towards the use of immune checkpoint inhibitors 97
The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives 96
Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications 94
Characterization of the metastatic behavior and gene expression profile (RNAseq) of different melanoma cell lines: a comprehensive in vivo model. 94
A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer 92
Non-Melanoma Skin Cancers: Biological and Clinical Features 92
Liquid biopsy in cervical cancer: Hopes and pitfalls 91
Assessment of bone turnover markers and DXA parameters to predict bone metastasis progression during zoledronate treatment: a single-center experience 90
Primary soft tissue sarcoma of the heart: An emerging chapter in cardio-oncology 90
Nivolumab + ipilimumab (N+I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés 90
Adamantinoma-like Ewing sarcoma of the salivary glands: a case report and systematic literature review 89
Understanding the mechanisms of resistance in EGFR-positive NSCLC: From tissue to liquid biopsy to guide treatment strategy 89
Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma 89
Hormone signaling pathways as treatment targets in renal cell cancer (Review) 89
Acute Kidney Injury in Cancer Patients 89
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 88
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand? 88
Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases 88
Beyond ras and braf: Her2, a new actionable oncotarget in advanced colorectal cancer 88
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 87
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study 86
Opening an onconephrology clinic: Recommendations and basic requirements 86
[Current approaches to the first-line treatment of clear-cell renal cell carcinoma] 86
Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis 86
Abstract 2012: In vitro validation of tumor-derived large extracellular vesicles isolation and characterization as suitable tool for liquid biopsy 85
Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer 85
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma 84
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 84
An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study 83
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions 83
Adjuvant therapy in renal cell carcinoma 82
Uterine carcinosarcoma: An overview 82
A Glimpse in the Future of Malignant Mesothelioma Treatment 82
Sarcoidosis-like reactions in metastatic renal cell carcinoma patients treated with immune-based combinations 80
Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma 79
Abstract 2808: Characterization of the metastatic behavior and gene expression profile (RNAseq) of different melanoma cell lines: a comprehensive in vivo model 78
Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 78
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis 78
An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study 78
Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium 77
Choosing the right cell line for renal cell cancer research 77
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial 77
Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer 76
Targeting stim and Orai proteins as an alternative approach in anticancer therapy 76
Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trial 76
Playing the devil’s advocate: Should we give a second chance to mTOR inhibition in renal clear cell carcinoma? – ie strategies to revert resistance to mtor inhibitors 76
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association with Survival 76
Onco-nephrology: A decalogue 75
ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma 75
The emerging role of PI3K inhibitors for solid tumour treatment and beyond 74
Development of extracellular matrix supported 3D culture of renal cancer cells and renal cancer stem cells 74
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 74
Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma 74
Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus 74
Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma 73
Metastatic renal cell carcinoma cells growing in 3D on poly‑D‑lysine or laminin present a stem‑like phenotype and drug resistance 73
Melanoma Brain Metastases: A Retrospective Analysis of Prognostic Factors and Efficacy of Multimodal Therapies 73
Mucosal Melanoma: Epidemiology, Clinical Features, and Treatment 72
MiT translocation renal cell carcinoma: A review of the literature from molecular characterization to clinical management 72
The role of the cell-cell interactions in cancer progression 72
An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy 72
Totale 9.697
Salva come PNG Salva come JPEG
Categoria #
all - tutte 115.514
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 115.514
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021165 0 0 0 0 0 0 0 0 0 0 0 165
2021/20221.506 271 22 10 16 66 161 24 40 150 147 224 375
2022/20231.201 235 152 136 22 73 138 137 77 150 10 20 51
2023/2024711 46 239 47 40 53 110 22 39 36 11 13 55
2024/20254.705 207 27 492 256 83 331 472 234 259 367 729 1.248
2025/202610.535 1.289 465 831 1.426 810 615 1.241 609 1.442 1.200 469 138
Totale 21.223